title: ZEB2/SIP1 as novel prognostic indicator in eyelid sebaceous gland carcinoma.
abstract: Epithelial-mesenchymal transition (EMT) plays a pivotal role in tumor invasion and metastasis in various malignancies. ZEB2/SIP1 is an important EMT regulator and down-regulates E-cadherin expression. The present study was planned to explore status of EMT-associated markers ZEB2/SIP1 and E-cadherin in eyelid sebaceous gland carcinoma (SGC) and to correlate with clinicopathological high-risk features. Expressions of ZEB2 and E-cadherin were evaluated by immunohistochemistry in 65 cases of histopathologically proven eyelid SGC. The results were correlated with clinicopathological high-risk features and survival of the patients to determine the prognostic significance of ZEB2, E-cadherin, and various high-risk features. Cytoplasmic overexpression of ZEB2 and membranous loss of E-cadherin were seen in 68% and 66% of cases of eyelid SGC, respectively. ZEB2 overexpression was significantly associated with E-cadherin loss (P = .002). Overexpression of ZEB2 also showed significant association with lymph node metastasis (P = .046), orbital invasion (P = .049), large tumor size (P = .018), and advanced tumor stages (P = .036). Survival analysis revealed that patients with ZEB2 overexpression had poor survival. ZEB2 overexpression and orbital invasion were found to be independent prognostic indicators (univariate analysis). However, multivariate analysis showed that ZEB2 (hazard ratio, 0.094; 95% confidence interval, 00.012-0.709; P = .022) was the best poor prognostic indicator of eyelid SGC. Our study demonstrates the role of both ZEB2 and E-cadherin in the promotion of EMT in eyelid SGC. The outcome of this study also points toward ZEB2 as an independent prognostic marker as well as a potential therapeutic target in eyelid SGC.
authors.affiliation: Department of Ocular Pathology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: mansi.aiims@gmail.com.
authors.forename: Mansi
authors.initials: M
authors.lastname: Bhardwaj
authors.affiliation: Department of Ocular Pathology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: ssenop@rediffmail.com.
authors.forename: Seema
authors.initials: S
authors.lastname: Sen
authors.affiliation: Department of Ocular Microbiology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: raianjana@rediffmail.com.
authors.forename: Anjana
authors.initials: A
authors.lastname: Sharma
authors.affiliation: Department of Ocular Pathology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: dr_skashyap@hotmail.com.
authors.forename: Seema
authors.initials: S
authors.lastname: Kashyap
authors.affiliation: Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: kunzangchosdol@yahoo.com.
authors.forename: Kunzang
authors.initials: K
authors.lastname: Chosdol
authors.affiliation: Department of Ophthalmology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: pushkern@hotmail.com.
authors.forename: Neelam
authors.initials: N
authors.lastname: Pushker
authors.affiliation: Department of Ophthalmology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: msbajaj32@hotmail.com.
authors.forename: Mandeep Singh
authors.initials: MS
authors.lastname: Bajaj
authors.affiliation: Department of Medical Oncology, Institute of Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: sambakh@hotmail.com.
authors.forename: Sameer
authors.initials: S
authors.lastname: Bakhshi
mesh_terms: D018266:Adenocarcinoma, Sebaceous / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D015820:Cadherins / Q000032:analysis / Q000096:biosynthesis; D058750:Epithelial-Mesenchymal Transition; D005142:Eyelid Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D005260:Female; D018398:Homeodomain Proteins / Q000032:analysis / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012097:Repressor Proteins / Q000032:analysis / Q000096:biosynthesis*; D012626:Sebaceous Gland Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D000074165:Zinc Finger E-box Binding Homeobox 2
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D018398:Homeodomain Proteins; D012097:Repressor Proteins; C492363:ZEB2 protein, human; D000074165:Zinc Finger E-box Binding Homeobox 2
keywords: E-cadherin; Epithelial-mesenchymal transition; Eyelid sebaceous gland carcinoma; Immunohistochemistry; ZEB2